PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer
Analysis of assay used in IMpassion130 to guide treatment of metastatic and advanced breast cancers
Using aspirin for cancer prevention
Shaping the future of metastasis - ecancer investigates
Comment: Critical quality attributes of biosimilars
Simplifying molecular subtypes of metastatic gastric cancer
VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Checkmate 227: Final analysis for the non small cell lung cancer trial